Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K Delta Inhibitor TGR-1202 in Myelofibrosis.

Drug Category:
Conference Category:
Lead Author: Moyo et al.
Published Date: 05/12/2016
Download Link: /wp-content/uploads/2019/03/ASH%202016%20Moyo%20Final.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top